 | This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (August 2023) (Learn how and when to remove this message) |
 | This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "BiondVax" – news · newspapers · books · scholar · JSTOR (August 2023) (Learn how and when to remove this message) |
 | |
| Company type | Public |
|---|---|
| Traded as | Nasdaq: BVXV |
| Industry | Pharmaceuticals |
| Founded | 2003; 21 years ago (2003) |
| Headquarters | Jerusalem, Israel |
| Number of employees | 30 (2022) |
| Website | www |
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases.
In collaboration with the Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax develops nanosized antibody (NanoAb) therapies for diseases such as COVID-19, asthma and psoriasis.
History
Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and owns and operates a biologics manufacturing facility for housing its laboratories, production facilities and offices.
In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences – and the UMG to enter into a strategic collaboration for the development and commercialization of COVID-19 NanoAbs.